Limited Time Offer: Buy One bag of any Salters dog food and receive a 150g bag of Salters treats FREE at checkout

This Product cannot be purchased without a prescription

Marbocyl Injectable antibiotic - Pet Health Direct
Marbocyl Injectable antibiotic - Pet Health Direct
  • Load image into Gallery viewer, Marbocyl Injectable antibiotic - Pet Health Direct
  • Load image into Gallery viewer, Marbocyl Injectable antibiotic - Pet Health Direct

Marbocyl Injectable antibiotic

Regular price
£68.49
Sale price
£68.49
Regular price
Sold out
Unit price
per 
Tax included. Shipping calculated at checkout.
0%

Are you aware of the relevant safety precautions relating to the product?

Have you used this before?

Before this medication can be dispensed you will need to log in and select the pet that it is for. Click here to login

Marbocyl is relatively recently developed antibiotic available in doses for pigs and cattle. It has a broad spectrum of activity and can be used in infections affecting the skin, respiratory system, urinary systems and other soft tissues. Appropriate culture and sensitivity testing of the infectious agent is advised where possible. For mild and localised infections a course lasting a few days is all that is needed, but some infections, such as those involving the deeper layers of the skin, will require a course lasting several weeks. Marbocyl tablets should be given once daily

Directions for Use:

Marbocyl™ 2% Solution for Injection

Presentation

Marbocyl 2% is presented as a sterile solution for injection.

Marbofloxacin 2.0% w/v

Disodium edetate 0.01% w/v

Thioglycerol 0.05% w/v

Metacresol 0.2% w/v

Uses

In pre-ruminant cattle up to 100kg bodyweight and pigs, Marbofloxacin 2 % is indicated in the treatment of respiratory infections caused by susceptible strains of organisms.

Dosage and administration

The recommended dosage is 2 mg/kg/day (1 ml/10 kg) in a single daily injection by subcutaneous or intravenous routes in cattle and by the intramuscular route in pigs.

Treatment duration is 3 - 5 days by the intravenous route in cattle,. 3 days by the subcutaneous route in cattle,. and 3 - 5 days by the intramuscular route in pigs.

The volume of injection should be limited to 10ml at each site of injection for pigs.

In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.

Contra-indications, warnings, etc

Special Precautions for use in Animals

Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Wherever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

No severe side-effects are to be expected at doses up to 5 times the recommended dose in cattle and pigs. In particular no lesions of the articular joints are encountered.

Subcutaneous injection is well tolerated. Transitory inflammatory reactions are sometimes observed at the injection site, but without clinical impact.

Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.

Operator Warning

People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.

Withdrawal periods

Preruminating calves (up to 100kg bodyweight): 6 days

Pigs: 4 days

Pharmaceutical precautions

Following withdrawal of the first dose, use the product within 28 days. Discard unused material.

Do not store above 25°C. Protect from light.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Manure and slurry containing marbofloxacin should not be spread on the same area of land in successive years.

Legal category

Packaging quantities

Packaged in amber type II glass vials of 10, 20, 50ml, 100 ml and 250ml.

The vials are closed with a chlorobutyl rubber stopper oversealed with aluminium caps.

Each vial is packaged in a cardboard box.

Not all pack sizes may be marketed.

Further information

ATC Vet Code: QJ01MA93

Pharmacodynamic properties

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Campylobacter jejunii, Citrobacter, Enterobacter, Proteus spp, Klebsiella spp Actinobacillus pleuropneumoniae, Bordetella bronchiseptica, Pasteurella haemolytica, Pasteurella multocida, Haemophilus spp, Moraxella spp, Pseudononas aeruginosa) as well as Mycoplasma (Mycoplasma bovis, Mycoplasma dispar, Mycoplasma hyopneumoniae).

Resistance to Streptococcus may occur.

Pharmacokinetic properties

After subcutaneous administration in cattle and pigs at the recommended dose of 2 mg/kg, marbofloxacin is readily absorbed and its bioavailability is close to 100 %. It is weakly bound to plasma proteins (less than 10 % in pigs and 30 % in cattle), extensively distributed and, in most tissues (liver, kidney, skin, lung, bladder, uterus, digestive tract), it achieves higher concentrations than in plasma.

In cattle, marbofloxacin is eliminated slowly in pre-ruminating calves (t1/2β = 5-9 h) predominantly in the active form in urine (3/4) and faeces (1/4).

In pigs, marbofloxacin is eliminated slowly (t1/2β = 8-10 h) predominantly in the active form in urine (2/3) and faeces (1/3).

Marketing Authorisation Holder (if different from distributor)

Marketing Authorisation Number

Vm 06462/4005.

Marbocyl™ 10% Solution for Injection

Presentation

Solution for Injection. Each 100ml contains marbofloxacin 10g, monothioglycerol 0.1g, metacresol 0.2g and disodium edetate 0.01g

Uses

In cattle: Indicated in the treatment of respiratory infections caused by susceptible strains of organisms. It is also indicated in the treatment of acute E.coli mastitis.

In pigs: Indicated in the treatment of Metritis Mastitis Agalactia syndrome caused by susceptible strains of organisms.

Dosage and administration

The recommended dose rate is 2mg/kg/day (1ml/50kg) in a single daily injection by intramuscular, subcutaneous or intravenous routes in cattle and by intramuscular route in pigs.

Treatment durations are 3 days in pigs and 3 to 5 days in cattle.

In order to reduce the risk of particulate contamination of the product, it is recommended that a draw-off needle be used to reduce the number of times the septum is punctured.

Contra-indications, warnings, etc

Withdrawal periods

Milk for human consumption must not be taken during treatment. Milk for human consumption may only be taken from cattle after 36 hours from the last treatment.

Animals must not be slaughtered for human consumption during treatment. Cattle may be slaughtered for human consumption only after 6 days from the last treatment. Pigs may be slaughtered for human consumption only after 4 days from the last treatment.

Overdosage may cause acute signs in the form of neurological disorders which should be treated symptomatically.

General precautions: No severe side-effects are to be expected at doses up to 3 or 5 times the recommended dose in cattle and pigs respectively. In particular, no lesions of the articular joints are encountered.

Intramuscular or subcutaneous injections are well tolerated although transitory inflammatory lesions without clinical impact can occur at the injection site.

May be used in pregnant and lactating cows and sows.

Special precautions for use in animals

Official and local antimicrobial policies should be taken into account when the product is used. Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials. Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevelance of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

Operator warnings

People with known hypersensitivity to fluoroquinolones should avoid using this product. Wash hands after use.

Pharmaceutical precautions

Do not store above 25°C and protect from light.

Following withdrawal of the first dose, use the product within 28 days. Any unused material should be discarded.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Manure and slurry containing marbofloxacin should not be spread on the same area of land in successive years.

Legal category

Packaging quantities

Amber type II glass vials of 20, 50, 100 and 250ml. The vials are closed with a chlorobutyl rubber stopper oversealed within aluminium caps. Each vial is packaged in a cardboard box. Not all pack sizes may be marketed.

Further information

ATC Vet code: QJ01MA93

Pharmacodynamic properties:

Marbofloxacin is a synthetic, bactericidal antimicrobial, belonging to the fluoroquinolone group which acts by inhibition of DNA gyrase. It is effective against a wide range of Gram positive bacteria (in particular Staphylococci) and Gram negative bacteria (Escherichia coli, Salmonella typhimurium, Citrobacter freundii, Enterobacter cloacae, Serratia marcescens, Morganella morganii, Proteus spp, Klebsiella spp, Shigella spp, Pasteurella spp, Haemophilus spp, Moraxella spp, Pseudomonas spp) as well as Mycoplasma spp.

Pharmacokinetic properties:

After subcutaneous or intramuscular administration in cattle and intramuscular administration in pigs at the recommended dose of 2mg/kg, marbofloxacin is readily absorbed and reaches maximal plasma concentrations of 1.5microgram/ml within less than 1 hour. Its bioavailability is close to 100%. It is weakly bound to plasma proteins (less than 10% in pigs and 30% in cattle), extensively distributed and in most tissues (liver, kidney, skin, lung, bladder, uterus, digestive tract) it achieves a higher concentration than in plasma.

In cattle, marbofloxacin is eliminated slowly in pre-ruminating calves (t1/2β = 5-9h) but faster in ruminant cattle (t1/2β = 4-7h) predominantly in the active form in urine (¾ in pre-ruminating calves, ½ in ruminants) and faeces (¼ in pre-ruminating calves, ½ in ruminants).

In pigs, marbofloxacin is eliminated slowly (t1/2β = 8-10h) predominantly in the active form in urine (2/3) and faeces (1/3).

Marketing Authorisation Holder (if different from distributor)

Marketing Authorisation Number

Vm 06462/4003

Datasheets:

Marbocyl™ 2% Solution for Injection

Marbocyl™ 10% Solution for Injection